Compare CNXC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | VRDN |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.7B |
| IPO Year | 2020 | 2014 |
| Metric | CNXC | VRDN |
|---|---|---|
| Price | $27.27 | $18.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $54.80 | $38.25 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,825,771,000.00 | $5,706,000.00 |
| Revenue This Year | $5.17 | $27.65 |
| Revenue Next Year | $2.51 | $253.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $24.27 | $9.90 |
| 52 Week High | $62.14 | $34.29 |
| Indicator | CNXC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 23.68 |
| Support Level | $24.27 | $17.91 |
| Resistance Level | $34.64 | $19.42 |
| Average True Range (ATR) | 2.23 | 1.12 |
| MACD | -0.20 | -1.02 |
| Stochastic Oscillator | 29.84 | 13.93 |
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).